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Head and neck and lung cancer
Approximately 5% of all cancers develop in the mucosa of
the head and neck area (Boyle et al., 1990). A substantial
number of these patients present at a moment that curative
treatment is possible, due to the fact that many head and
neck cancers cause complaints in an early stage. The prog-
nosis of TINO and T2NO glottic laryngeal cancer, for
instance, is in the order of 90 and 70% 5 year survival
respectively.
It is very likely that the pathogenesis of head and neck
cancer is multifactorial. Both tobacco and alcohol are impor-
tant risk factors in oral, oropharyngeal, hypopharyngeal and
laryngeal cancer (Wynder et al., 1956, 1976; Williams &
Horn, 1977; Tuyns, 1979; Rothman et al., 1980). In addition,
it is very likely that an individual genetic susceptibility (de
Vries et al., 1987a, 1987b; Schantz & Hsu, 1989; Spitz et al.,
1989; Schantz et al., 1990) is important if only because so
many individuals have been and are being exposed to
tobacco and alcohol, whereas only relatively few actually
develop cancer in the upper air- and food passages. Patients
with head and neck cancers are prone to develop multiple
primary cancers (see further), probably because the mucosa
of the upper air and food passages is being exposed to the
same carcinogens.
The situation in lung cancer patients is different from that
of head and neck cancer patients. Lung cancer is the leading
cause of cancer deaths in men and the second leading cause
of cancer deaths in women, after cancer of the breast. The
major factor in the development oflung cancer is the inhala-
tion of tobacco smoke, by susceptible hosts. In contrast to
head and neck cancer patients, most lung cancer patients
already have a poor prognosis at the time ofdiagnosis. The 5
year survival rate for all stages oflung cancer has been about
9% for the last 20 years. This small subpopulation of
patients that will be cured from their lung cancer are unfor-
tunately prone to develop second primary cancers as well.
Multiple primary tumours occurs in 10-30% of all
patients with head and neck cancer and in 10% of patients
with, lung cancer (Vrabec, 1979; Gluckman & Crissman,
1983; Tepperman & Fitzpatrick, 1981; Gluckman, 1983;
Wagenfeld et al., 1981; Hordijk & de Jong, 1983; de Vries &
Snow, 1986; de Vries et al., 1986; De Vries, 1990, and many
others). The great majority of these second primary cancers
occur metachronously in the respiratory tract and upper
digestive tract.
These second primary tumours usually carry a bad prog-
nosis because they often occur either at notoriously bad sites,
like (again in) the lung or esophagus, or within previously
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treated areas within the head and neck, defying curative
treatment. Improvements in local/regional control rates in
head and neck cancer patients have not resulted in a propor-
tional increase in survival rates in these patients. The reason
for this is that as fewer patients die from uncontrolled disease
in the head and neck, more patients are exposed to the risk
of second primary tumours (and distant metastases)
(Goepfert, 1984). Second tumours are the most important
cause of death in cured (early stage) head and neck cancer
patients.
In principle, two approaches are possible to combat the
problem of second tumours in head and neck and lung
cancer patients: early detection and (chemo-)prevention.
Regarding early detection, it has become common practice at
many centres to perform panendoscopy during the initial
work-up of head and neck cancer patients. However, most
second tumours occur metachronously. Regular, e.g. half
yearly panendoscopy has been shown to be not feasible. As a
result many second tumours are still being detected beyond a
curable stage during follow-up.
Chemoprevention
Chemoprevention offers a more attractive approach. Many
animal, in vitro and epidemiological studies have shown a
protective effect of Vitamin A and the other retinoids (the
synthetic and natural analogs of Vitamin A). Several clinical
chemoprevention trials with beta-carotene, Vitamin A and
other retinoids are at present being carried out. Chemo-
preventive agents working along other mechanisms are also
currently being tested.
In general, two different approaches are used in chemo-
prevention trials. In many trials in the United States, relative
low doses of retinoids, or vitamin A, beta-carotene or both
are administered, aiming at restoration to normal levels. This
approach is used in persons at relatively low risk, with high
compliance, and has little risk of side effects or serious
toxicity. The other approach is to use high doses, in which
more activity at promotion/progression phases of cancer
development is to be expected. This approach is better suited
for high risk groups. Side-effects can be expected, but doses
are kept below the threshold above which serious toxicity can
be expected.
Curatively treated and early stage head and neck cancer
and lung cancer patients form an ideal population to test the
value of chemopreventive medication because of the extreme-
ly high risk to develop second tumours. In these high risk
groups, three interesting chemopreventive studies were initiat-
ed several years ago, which will be discussed.
M D Anderson study
Hong et al. (1990) from the M D Anderson Institute recently
published the results of their study in cured head and neck
cancer patients in which 13-cis-retinoic acid (isotretinoin)
50-100 mg m 2 of body surface area during 12 months was
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used. In this study in which 103 patients were entered, only
two second tumours occurred in the isotretinoin group, as
compared to 12 (24%) in the placebo group. These data
showed for the first time that chemoprevention of second
tumours in head and neck cancer patients is possible. In apite
of these exciting results, a word of caution is warranted for
four reasons:
(a) The toxicity of 13-cis-retinoic acid in the dose used, was
considerable and defies further treatment with 13-cis-
retinoic acid in this dose. One of the conclusions of the
authors was that further research into the use of lower
doses of 13-cis-retinoic acid or other less toxic medica-
tion (such as Vitamin A) is needed.
(b) The number of patients in the study was limited.
(c) The number of second tumours in the untreated group
(24%) after 32 months is exceptionally high (one would
expect 5-10% after 30 months), whereas the number of
second tumours (2%) in the untreated patients is excep-
tionally low. The results are almost too good to be true
and one wonders whether the results are due to the
treatment effect only, or whether a coincidental factor -
especially in the placebo group - is playing a role. The
encouraging data from this study therefore need to be
confirmed by other studies.
(d) All stages of head and neck cancer patients were eligible
instead of early stage patients only. In general, chemo-
prevention is especially indicated in early stage head and
neck cancer patients since these patients have the best
prognosis with regard to their 'index'-tumour, whereas
the prognosis is advanced stage cancer patients is rela-
tively more dependent on the primary tumour itself.
The Milan Trial
A randomised chemoprevention trial in lung cancer patients
was initiated in 1984 at the National Cancer Institute of
Milan, and started in July 1985 (Pastorino et al., 1991b).
Patients with pathological diagnosis of stage 1 (T1-T2, NO,
MO) non-small cell lung carcinoma after complete surgical
resection were selected for entry. Aims of the trial were (a) to
investigate the tolerability of high dose retinol palmitate
(vitamin A) administered for a long period of time; (b)
evaluate the effect of retinol palmitate on the frequency of
recurrences of initial lung cancer; (c) evaluate the efficacy of
retinol palmitate to prevent or delay the occurrence of second
primary cancers. Patients were randomly assigned to either
vitamin A treatment or control without treatment, stratified
according to the centre, cell type (squamous vs non-squa-
mous) and previous cancer at another site (absent vs cured).
The accrual was closed in 1989, and follow-up of all patients
was updated in July 1990. Between July 1985 and October
1989, 313 patients entered the trial and 307 were evaluable
for the analysis: 150 in the treatment arm and 157 in the
control arm. At a median follow-up of 29 months, a total of
113 (37%) patients have failed after treatment: 47 (31%) in
the treated arm and 66 (42%) in the control arm (P = 0.051).
A total of 35 second primary cancers were detected in 32
patients: 14 (9%) in the treatment arm and 21 (13%) in the
control arm. Three patients in the control arm developed
more than one second primary tumour and another patient
had both a recurrence and a second primary tumour. Exclud-
ing those second primary tumours which were clearly
unrelated to the chemoprevention target (colon, prostate,
melanoma), the total number ofpatients who failed was 43 vs
63 (P = 0.035). The probability of disease-free survival (time
to recurrence or second primary cancer) at 5 years resulted in
61 vs 48% in favour of the treatment arm (P<0.05) and the
overall estimated survival at 5 years was 66% vs 57%
(P = 0.3). The authors concluded from this preliminary ana-
lysis that daily oral administration of retinol palmitate was
effective in reducing the number of cancer failures and
improving the disease-free survival in patients curatively
resected for stage I lung cancer, although it did not signi-
ficantly reduce the incidence of second primary tumours. A
longer follow-up will be necessary to provide a clearcut
demonstration of the chemopreventive potential of high-dose
vitamin A in this patient population.
Euroscan
A further, much larger chemoprevention study in head and
neck cancer and lung cancer patients is EUROSCAN
(EUROSCAN Steering Committee, 1990; de Vries et al.,
1990). EUROSCAN is an European chemoprevention study
in curatively treated patients with oral cancer, laryngeal
cancer and lung cancer which started in June 1988 under the
responsibility of the European Organisation of Research and
Treatment of Cancer (EORTC). In contrast to Hong's et al.
(1990) study, in EUROSCAN only early stage patients are
eligible. As chemopreventive drugs Retinyl Palmitate
300.000 IU daily during 1 year and half this dose during a
second year, or N-acetyl-cysteine 600 mg during 2 years, or
both drugs or neither are being used, in a 2 x 2 factorial
design (Stampfer et al., 1985). The rationale for the choice of
these two drugs will be discussed.
Vitamin A
In vivo, in vitro and in nutritional epidemiological studies,
vitamin A and its precursor beta-carotene have been found
to be protective against the development of epithelial cancers
(Peto et al., 1981; Colditz et al., 1987; Byers, 1988).
Epidemiological studies have shown a higher risk of lung
cancer in individuals with low intake and/or serum levels of
retinol, or beta-carotene (Ziegler et al., 1984; Byers et al.,
1984; Menkes et al., 1986; Middleton et al., 1986).
Several serum studies have found that low serum levels of
vitamin A and/or beta-carotene are correlable with head and
neck squamous cell cancer and/or lung cancer (Bichler &
Daxenbichler, 1982; Fex et al., 1986; Friedman et al., 1986).
We recently compared serum levels of vitamin A, vitamin E
and beta-carotene in patients with head and neck cancer with
and without second primary tumours (SPT's) (de Vries &
Snow, 1990) and it was found that in 24 head and neck
cancer patients with SPT's the serum levels of vitamin A
were lower than in 71 patients with single head and neck
cancers.
It was felt that safe drugs were needed in an experimental,
large scale study as EUROSCAN was meant to be. Vitamin
A has proven to be a relatively safe and non-toxic drug, even
when given in high doses and for a long period (Silverman et
al., 1963; Bendich et al., 1989). Retinol Palmitate in an
emulsified form has optimal features with regard to intestinal
absorbtion, availability from the tissue, with limited liver
toxicity. It has been used for many years for skin diseases
with acceptable side effects. Based on experience in skin
diseases such as psoriasis, ichtyosis and skin cancer, the dose
of 300,000 IU daily yields justifiable side effects with com-
parable response rates as in higher doses.
N-Acetylcysteine
N-Acetylcystein (NAC) has attracted attention as a possible
chemopreventive agent (van ZandwiUk, 1991). NAC is a pre-
cursor of extracellular and intracellular glutathione (GSH)
(de Flora et al., 1985; Cotgreave et al., 1986) and it is widely
used in the treatment of patients with chronic bronchitis and
emphysema. It has become popular for its potent anti-oxi-
dant/de-toxificant properties. NAC is for instance effective
treatment for preventing fatal oxidative liver damage in para-
cetamol poisoning (Prescott et al., 1979). NAC has also been
shown to give local protection of the urinary tract against
iphosphamide and cyclophosphamide induced toxicity
(Holoye et al., 1983). In vitro, NAC is able to inhibit
mutagens such as aflatoxin, benzpyrene and cigarette smoke
condensate (de Flora, 1984; de Flora et al., 1984, 1989). It
prevents chemically induced lung and colon tumours in
experimental animals. NAC added before and after the car-THE EUROSCAN STUDY 987
cinogen exposure significantly reduced the incidence and
multiplicity of lung tumours in mice and of colon tumours in
the rat (de Flora et al., 1986; Wilpart et al., 1986). Evidence
has also been provided for the ability of NAC to inhibit
DNA adduct formation by either ingested or inhaled carcino-
gens (de Flora et al., 1991). The results suggest that it is
possible to prevent chemically induced cancers by drugs that
raise the levels of physiologically trapping agents such as
GSH and that NAC should at least be effective at the
initiation stage of carcinogenesis. The significance of anti-
oxidant protection is also underlined by the confirmation of
an association between low levels of serum vitamin E and the
risk of lung cancer (Byers et al., 1984). Thus, the restoration
of physiological levels of trapping agents in patients who
have already had a tumour seems to be an important first
step in the prevention of a second tumour. The anticarcino-
genic effect of NAC is of particular interest since as men-
tioned earlier, the drug is safe, without major side effects at
the dose of 600 mg/daily and it had been widely used in the
treatment of patients with chronic lung disease (Ferrari, 1980).
Vitamin A and N-acetylcysteine
The combination of the two drugs was chosen for the follow-
ing reasons. NAC is supposed to be active in early stages of
carcinogenesis: before and possibly shortly after the occur-
rence of DNA damage. Vitamin A is thought to act late
during carcinogenesis: in the promotion and progression
phases.
NAC as single drug could be active as well as vitamin A,
while the combination theoretically covers almost the whole
carcinogenic process. No interaction with regard to side
effects are expected from the combination.
End points
In total 2,000 patients are planned because the endpoints of
EUROSCAN do not only consist of the number of second
tumours, local/regional recurrence and distant metastases,
but also include long term survival rates.
In the United States of America, much effort at present is
devoted to the development of so-called biomarkers as inter-
mediate endpoints in chemoprevention trials (Lippman et al.,
1990; Schatzkin et al., 1990). It is hoped that biomarkers
eventually will be identified which are related to epithelial
carcinogenesis and which can serve as surrogate endpoint in
the conduct of future chemoprevention trials. They would
enable us to perform much more chemoprevention studies
with less patients, less costs and in less time, than studies that
use malignancy as the endpoint.
In EUROSCAN study of biomarkers as intermediate end-
points is as yet not included. Although from a research point
of view it appears attractive to incorporate research into
biomarkers as intermediate endpoints in EUROSCAN, it has
to be realised that it is uncertain whether valid biomarkers
will ever be found. Until that time, trials using malignancy as
endpoint will provide the most valuable information.
Accrual per June 1990
The study started on 1 June 1988. The following data were as
on 1 June 1991. Eight hundred and fifty-three of the 2,000
patients planned had entered the study at that time. The
mean accrual at present is 40 new patients per month. The
accrual is still rising: in 1988, 31 patients; in 1989, 135
patients; in 1990, 461 patients and in 1991 until 1 June, 226
patients were entered. It is estimated that the accrual of the
next 1,150 patients will take another 2-3 years.
More than 30 cancer centres from 13 European countries
are entering patients. Centres from The Netherlands (313
patients), Italy (290), Germany (62), Spain (51), Belgium
(34), Yugoslavia (29), Poland (20), Czechoslovakia (17),
Turkey (12), Hungary (9), Portugal (8), France (5) and Great
Britain (3) had brought patients in the trial.
The division in the head and neck cancer patients (n = 506)
for the different sites was as follows: glottic laryngeal cancer,
227 patients; subglottic laryngeal cancer, 4 patients; supra-
glottic cancer, 84 patients and oral cancer, 141 patients. Of
the lung cancer patients (n = 347), there were 210 squamous
cell cancer and 137 non-squamous cell carcinomas.
In 554 patients with sufficient follow-up per 1 June 1991,
no evidence of disease in 476 patients, local recurrence in 46
patients, distant metastases in 19 patients, local and distant
metastases in two patients and second primaries in 11
patients were found.
Side effects and toxicity
Retinyl Palmitate
Pastorino et al. (199la) reported on the side-effects of Retinyl
Palmitate (300,000 IU daily for at least 12 months, the same
dose as in the first year of EUROSCAN) administration as
adjuvant treatment for resected stage I lung cancer. After a
median follow-up of 28 months, 283 patients could be evalu-
ated: 138 allocated to treatment with Retinyl Palmitate and
145 to standard treatment. The clinical results available do
well justify a continuation of vitamin A in this dose. Skin
dryness and desquamation were the most frequent symptoms,
affecting 60% of the treated patients. Other symptoms such
as dyspepsia, headache, nosebleeds and mild hairloss occur-
red in less than 10% of patients and were self terminating.
Only in four (3%) patients the treatment had to be inter-
rupted because of symptoms potentially related to vitamin A
administration. It was concluded that high dose Retinyl Pal-
mitate administration is a well-tolerated and safe treatment.
EUROSCAN
The side-effects in the 554 patients with sufficient follow-up
as preliminary noted per 1 June 1991 for the four treatment
arms [(1) Vitamin A and NAC (n = 135); (2) Vitamin A
(n = 143); (3) NAC (n = 140) and (4) no drugs (n = 136)]
were as follows:
No side effects were found for the four treatment arms in
55, 64, 82 and 99 paients, respectively.
Present, but well tolerated side-effects were found in 25, 21,
12 and 0 patients, respectively.
Poorly tolerated side-effects were noted in 14, 9, 2 and 0
patients, respectively.
Unbearable side-effects were noted in 14, 9, 2 and 0
patients, respectively. The most common side-effects were
dryness, desquamation and itching of the skin, headache and
dyspepsia.
It can be concluded that this intermediate analysis of
side-effects and toxicity in the first 554 patients of EURO-
SCAN has shown that both the single drugs, as well as the
combination treatment is well tolerated and that the toxicity
is mild and compares favourably with the earlier mentioned
intervention scheme as was used by Hong et al. (1990).
Conclusion
Chemoprevention of second primary tumours in head and
neck cancer patients and in lung cancer patients (Pastorino et
al., 1988) respectively, is developed from an interesting theo-
retical model into a realistic adjuvant treatment. The exciting
data from the study performed by Hong et al. (1990) need
confirmation by larger studies, using drugs less toxic while
hopefully equally effective.
The EUROSCAN study is until now running successfully988 N. DE VRIES et al.
throughout Europe. It is to be hoped that it will give an
answer whether this at present still experimental treatment
modality will eventually develop into a realistic intervention
in cured head and neck cancer and lung cancer patients.
When this will be so, it might be that in the future chemo-
preventive agents will be routinely applied in these extremely
high risk patients. At present however, the ideal drug or drug
combination, the dose and the duration of administration,
have still to be established.
Finally, when chemoprevention of cancer can be reached
in high risk groups, other populations at risk, e.g. patients
with premalignant lesions, or patients who have been expos-
ed to carcinogenic stimuli as asbestos workers, or even the
general population may eventually benefit from intervention
measures which currently are being tested in those who are at
the highest risk for 'the overshadowing threat for early stage
head and neck cancer patients' (Lippman & Hong, 1989).
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